This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Altimmune’s 8K filing here.
About Altimmune
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Featured Articles
- Five stocks we like better than Altimmune
- What Investors Need to Know to Beat the Market
- The Great CPU Race: AMD and Intel Battle for Dominance
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- 5 Top Rated Dividend Stocks to Consider
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
